ZAG/Sullivan Client Clear Genetics Acquired by Invitae
ZAG/Sullivan represented Clear Genetics, a leading developer of software for providing genetic services at scale, in its $50 million acquisition by Invitae Corporation (NYSE: NVTA), a leading medical genetics company. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care.
Clear Genetics' chatbot, named Gia, is an easy-to-use platform that guides patients throughout the genetic testing process and is currently being used by customers in Invitae's direct channel. Gia was developed in collaboration with genetic counselors to ensure information is offered in a medically responsible way. Gia can guide patients regarding consent, personalized risk assessment, insurance benefits, pre/post-test education and understanding their test results, all through an intuitive online conversation. Patients ask Gia questions throughout the process, and Gia uses natural language processing to respond with the resources they need.
"We founded Clear Genetics with a mission to simplify the genetic testing process for as many people as possible by providing easy-to-use, automated tools that help both patient and clinician from initial appointment to results," said Moran Snir, co-founder and chief executive officer of Clear Genetics. "Our shared mission to bring genetics to mainstream medicine makes joining Invitae the perfect next step on our path to delivering better healthcare and personalized treatment options globally."
In addition to Gia, Clear Genetics' Clinic Hub provides clinicians with similarly easy-to-use software to help manage patient care, including, for example, automated patient triage. The company's software has been deployed at leading health systems and clinics around the country, such as Geisinger and Huntsman Cancer Institute, among others.
"Clear Genetics' technologies have been designed to meet the needs of clinicians. In some ways, they can be thought of as a digital navigator for using genetic testing to care for patients," said Robert Nussbaum, chief medical officer of Invitae. "Clear Genetics, like Invitae, developed these tools with the goal of ensuring easier access to medically responsible, actionable genetic testing. Understanding how best to expand the use of these technologies will play an important role in answering how clinicians will harness the power of genetics in mainstream medicine."
Led by Scott Kaufman and Oded Har-Even, the ZAG/Sullivan team included David Guadagnoli, Amy Sheridan, Doug Stransky, Assaf Ariely, Patrick Driscoll, Roy Andersen, Howard Berkenblit, Corinne Hood Greene, David Kaplan, Jeffrey Karp, Eric Rietveld and Mitchell Stein, along with the cooperation of Adv. Eliav Azulay Oz from Lglbiz.
ZAG/Sullivan is an international law firm with offices in Israel, the United States, China, and the United Kingdom. The firm’s attorneys specialize in all disciplines of commercial law for both publicly held and private companies, with particular expertise in hi-tech, life science, international transactions, and capital markets. ZAG/Sullivan provides result-driven legal and business advice to its clients, addressing all aspects of the clients’ business activities, including penetration into new markets in strategic locations. In recent years, the firm has acted on a majority of the equity and debt financing transactions by Israeli technology companies on the NASDAQ. It has been the firm’s experience that the best results, those that give our clients the competitive advantage they need, are attained by coupling professional experience, global presence, and connections with the investor communities in Israel and abroad.